PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ontruzant

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Cancer

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...

February 2, 2022

Samsung Bioepis Launches Ontruzant (trastuzumab- biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

Samsung Bioepis Launches Ontruzant (trastuzumab- biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

August 11, 2020

Samsung Bioepis Reports Results of Ontruzant (biosimilar- trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locally Advanced HER2-Positive Breast Cancer

Samsung Bioepis Reports Results of Ontruzant (biosimilar- trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locall...

May 15, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us